儿童A族链球菌感染中毒性休克综合征的研究进展

王红玉; 周维; 黄丽素

doi:10.7499/j.issn.1008-8830.2503136

PDF(666 KB)

HTML

中国当代儿科杂志 ›› 2026, Vol. 28 ›› Issue (1) : 120-127. DOI: 10.7499/j.issn.1008-8830.2503136

综述

儿童A族链球菌感染中毒性休克综合征的研究进展

王红玉 ¹ (综述) ,
周维 ² ,
黄丽素 ¹ (审校)

作者信息 +

Research progress on toxic shock syndrome due to group A Streptococcus infection in children

Author information +

文章历史 +

摘要

儿童链球菌中毒性休克综合征是一种由链球菌感染引发的严重并发症，临床表现以急性休克和多器官功能障碍为主要特征。该病病情危重、病死率高，早期诊断和治疗是改善预后的关键。儿童群体患病后致死风险更高，且其发病机制复杂。该文旨在综述儿童A群链球菌感染所致链球菌中毒休克综合征的发病机制及诊疗进展，以期为改善临床预后、降低病死率提供参考。

Abstract

Streptococcal toxic shock syndrome in children is a severe complication of group A Streptococcus infection, characterized by acute shock and multiple organ dysfunction. It is a critical illness with high mortality, and early diagnosis and treatment are key to improving prognosis. Children with this syndrome have a higher risk of death, and the pathogenesis is complex. This review summarizes the pathogenesis and recent advances in the diagnosis and treatment of streptococcal toxic shock syndrome caused by group A Streptococcus infection in children, aiming to improve clinical outcomes and reduce mortality.

导出引用

王红玉, 周维, 黄丽素. 儿童A族链球菌感染中毒性休克综合征的研究进展[J]. 中国当代儿科杂志. 2026, 28(1): 120-127 https://doi.org/10.7499/j.issn.1008-8830.2503136

Hong-Yu WANG, Wei ZHOU, Li-Su HUANG. Research progress on toxic shock syndrome due to group A Streptococcus infection in children[J]. Chinese Journal of Contemporary Pediatrics. 2026, 28(1): 120-127 https://doi.org/10.7499/j.issn.1008-8830.2503136

参考文献

列表( 原文顺序 | 文献年度倒序 | 文中引用次数倒序 ) 可视化分析

[1]

Ikebe

, Okuno

, Uchitani

, et al. Serotype distribution and antimicrobial resistance of Streptococcus agalactiae isolates in nonpregnant adults with streptococcal toxic shock syndrome in Japan in 2014 to 2021[J]. Microbiol Spectr, 2023, 11(2): e0498722. PMCID: PMC10100893. DOI: 10.1128/spectrum.04987-22 .

https://www.ncbi.nlm.nih.gov/pubmed/36786620

本文引用 [1]

[2]

Kawai

, Miyoshi-Akiyama

, Katano

, et al. Invasive Streptococcus agalactiae (group B Streptococcus) infection with toxic shock-like syndrome: a report of a fatal non-pregnant case and a review of the literature[J]. J Infect Chemother, 2024, 30(1): 71-76. DOI: 10.1016/j.jiac.2023.09.003 .

https://www.ncbi.nlm.nih.gov/pubmed/37716644

[3]

Rajack

, Medford

, Ramadan

, et al. Emerging infection: streptococcal toxic shock-like syndrome caused by group B Streptococcus (GBS), Streptococcus agalactiae [J]. Autops Case Rep, 2024, 14: e2024497. PMCID: PMC11253910. DOI: 10.4322/acr.2024.497 .

https://www.ncbi.nlm.nih.gov/pubmed/39021470

[4]

Matsuoka

, Kimura

, Endo

, et al. Streptococcal toxic shock syndrome due to invasive coloproctitis caused by group G Streptococcus: a case report and literature review[J]. Cureus, 2023, 15(11): e48589. PMCID: PMC10710542. DOI: 10.7759/cureus.48589 .

https://www.ncbi.nlm.nih.gov/pubmed/38084186

本文引用 [1]

[5]	Tsao N, Chang YC, Hsieh SY, et al. AR-12 has a bactericidal Activity and a synergistic effect with gentamicin against group A Streptococcus [J]. Int J Mol Sci, 2021, 22(21): 11617. PMCID: PMC8583967. DOI: 10.3390/ijms222111617 . https://www.ncbi.nlm.nih.gov/pubmed/34769046 本文引用 [4]

[6]	Nelson GE, Pondo T, Toews KA, et al. Epidemiology of invasive group A streptococcal infections in the United States, 2005-2012[J]. Clin Infect Dis, 2016, 63(4): 478-486. PMCID: PMC5776658. DOI: 10.1093/cid/ciw248 . https://www.ncbi.nlm.nih.gov/pubmed/27105747 本文引用 [1]

[7]	Cascais I, Losa A, Correia C, et al. Toxic shock syndrome: eighteen years of experience in a pediatric intensive care unit[J]. Cureus, 2024, 16(1): e52898. PMCID: PMC10891456. DOI: 10.7759/cureus.52898 . https://www.ncbi.nlm.nih.gov/pubmed/38406070 本文引用 [2]

[8]	Johnson AF, LaRock CN. Antibiotic treatment, mechanisms for failure, and adjunctive therapies for infections by group A Streptococcus [J]. Front Microbiol, 2021, 12: 760255. PMCID: PMC8601407. DOI: 10.3389/fmicb.2021.760255 . https://www.ncbi.nlm.nih.gov/pubmed/34803985 本文引用 [1]

[9]	国家儿童感染与过敏性疾病监测中心, 福棠儿童医学发展研究中心, 北京市儿科质控中心, 等. 儿童侵袭性A族链球菌疾病诊断专家共识（2025）[J]. 中华儿科杂志, 2025, 63(3): 238-242. DOI: 10.3760/cma.j.cn112140-20240831-00618 . https://www.ncbi.nlm.nih.gov/pubmed/39979097 本文引用 [1]

[10]

Mariani

, Gentili

, Pulcinelli

, et al. State of the art of invasive group A Streptococcus infection in children: a scoping review of the literature with a focus on predictors of invasive infection[J]. Children (Basel), 2023, 10(9): 1472. PMCID: PMC10528266. DOI: 10.3390/children10091472 .

https://www.ncbi.nlm.nih.gov/pubmed/37761433

本文引用 [1]

[11]	Factor SH, Levine OS, Schwartz B, et al. Invasive group A streptococcal disease: risk factors for adults[J]. Emerg Infect Dis, 2003, 9(8): 970-977. PMCID: PMC3020599. DOI: 10.3201/eid0908.020745 . https://www.ncbi.nlm.nih.gov/pubmed/12967496 本文引用 [1]

[12]	Shepherd FR, Davies K, Miners KL, et al. The superantigens SpeC and TSST-1 specifically activate TRBV12-3/12-4⁺ memory T cells[J]. Commun Biol, 2023, 6(1): 78. PMCID: PMC9854414. DOI: 10.1038/s42003-023-04420-1 . https://www.ncbi.nlm.nih.gov/pubmed/36670205 本文引用 [1]

[13]	Castro SA, Dorfmueller HC. A brief review on group A Streptococcus pathogenesis and vaccine development[J]. R Soc Open Sci, 2021, 8(3): 201991. PMCID: PMC8074923. DOI: 10.1098/rsos.201991 . https://www.ncbi.nlm.nih.gov/pubmed/33959354 本文引用 [1]

[14]	Tuffs SW, Dufresne K, Rishi A, et al. Novel insights into the immune response to bacterial T cell superantigens[J]. Nat Rev Immunol, 2024, 24(6): 417-434. DOI: 10.1038/s41577-023-00979-2 . https://www.ncbi.nlm.nih.gov/pubmed/38225276 本文引用 [2]

[15]	Bergsten H, Nizet V. The intricate pathogenicity of group A Streptococcus: a comprehensive update[J]. Virulence, 2024, 15(1): 2412745. PMCID: PMC11542602. DOI: 10.1080/21505594.2024.2412745 . https://www.ncbi.nlm.nih.gov/pubmed/39370779 本文引用 [2]

[16]	Atchade E, De Tymowski C, Grall N, et al. Toxic shock syndrome: a literature review[J]. Antibiotics (Basel), 2024, 13(1): 96. PMCID: PMC10812596. DOI: 10.3390/antibiotics13010096 . https://www.ncbi.nlm.nih.gov/pubmed/38247655 本文引用 [1]

[17]	Brouwer S, Rivera-Hernandez T, Curren BF, et al. Pathogenesis, epidemiology and control of group A Streptococcus infection[J]. Nat Rev Microbiol, 2023, 21(7): 431-447. PMCID: PMC9998027. DOI: 10.1038/s41579-023-00865-7 . https://www.ncbi.nlm.nih.gov/pubmed/36894668 本文引用 [1]

[18]

Proft

, Fraser

. Streptococcus Pyogenes Superantigens: Biological Properties and Potential Role in Disease[M]//Ferretti JJ, Stevens DL, Fischetti VA. Streptococcus Pyogenes: Basic Biology to Clinical Manifestations. 2nd ed. Oklahoma City (OK): University of Oklahoma Health Sciences Center, 2024.

本文引用 [1]

[19]	Lin L, Xu L, Lv W, et al. An NLRP3 inflammasome-triggered cytokine storm contributes to streptococcal toxic shock-like syndrome (STSLS)[J]. PLoS Pathog, 2019, 15(6): e1007795. PMCID: PMC6553798. DOI: 10.1371/journal.ppat.1007795 . https://www.ncbi.nlm.nih.gov/pubmed/31170267 本文引用 [1]

[20]	Song L, Li X, Xiao Y, et al. Contribution of Nlrp3 inflammasome activation mediated by suilysin to streptococcal toxic shock-like syndrome[J]. Front Microbiol, 2020, 11: 1788. PMCID: PMC7456889. DOI: 10.3389/fmicb.2020.01788 . https://www.ncbi.nlm.nih.gov/pubmed/32922370 本文引用 [1]

[21]	Frost HR, Guglielmini J, Duchêne S, et al. Promiscuous evolution of group A streptococcal M and M-like proteins[J]. Microbiology (Reading), 2023, 169(1): 001280. PMCID: PMC9993116. DOI: 10.1099/mic.0.001280 . https://www.ncbi.nlm.nih.gov/pubmed/36748538 本文引用 [1]

[22]	Toledo AG, Bratanis E, Velásquez E, et al. Pathogen-driven degradation of endogenous and therapeutic antibodies during streptococcal infections[J]. Nat Commun, 2023, 14(1): 6693. PMCID: PMC10593946. DOI: 10.1038/s41467-023-42572-0 . https://www.ncbi.nlm.nih.gov/pubmed/37872209 本文引用 [1]

[23]	Su MSW, Cheng YL, Lin YS, et al. Interplay between group A Streptococcus and host innate immune responses[J]. Microbiol Mol Biol Rev, 2024, 88(1): e0005222. PMCID: PMC10966951. DOI: 10.1128/mmbr.00052-22 . https://www.ncbi.nlm.nih.gov/pubmed/38451081 本文引用 [1]

[24]

Wierzbicki

, Campeau

, Dehaini

, et al. Group A streptococcal S protein utilizes red blood cells as immune camouflage and is a critical determinant for immune evasion[J]. Cell Rep, 2019, 29(10): 2979-2989.e15. PMCID: PMC6951797. DOI: 10.1016/j.celrep.2019.11.001 .

https://www.ncbi.nlm.nih.gov/pubmed/31801066

本文引用 [1]

[25]	Cook A, Janse S, Watson JR, et al. Manifestations of toxic shock syndrome in children, Columbus, Ohio, USA, 2010-2017[J]. Emerg Infect Dis, 2020, 26(6): 1077-1083. PMCID: PMC7258457. DOI: 10.3201/eid2606.190783 . https://www.ncbi.nlm.nih.gov/pubmed/32442091 本文引用 [1]

[26]	Zhang H, Dong J, Huang J, et al. Evaluating antibiotic regimens for streptococcal toxic shock syndrome in children[J]. PLoS One, 2023, 18(10): e0292311. PMCID: PMC10569614. DOI: 10.1371/journal.pone.0292311 . https://www.ncbi.nlm.nih.gov/pubmed/37824534 本文引用 [3]

[27]	Torimitsu S, Abe H, Makino Y, et al. Streptococcal toxic shock syndrome with fatal outcome: report on four forensic autopsy cases[J]. Leg Med (Tokyo), 2021, 50: 101851. DOI: 10.1016/j.legalmed.2021.101851 . https://www.ncbi.nlm.nih.gov/pubmed/33578046 本文引用 [2]

[28]	马耀玲, 何颜霞. 链球菌中毒性休克综合征[J] . 中华实用儿科临床杂志, 2022, 37(21) : 1633-1636. DOI: 10.3760/cma.j.cn101070-20220806-00945 本文引用 [1]

[29]

Hanada

, Wajima

, Takata

, et al. Additional biomarkers and emm types associated with group A streptococcal toxic shock syndrome: a Japanese nationwide observational study[J]. Eur J Clin Microbiol Infect Dis, 2025, 44(6): 1471-1480. PMCID: PMC12116948. DOI: 10.1007/s10096-025-05116-6 .

https://www.ncbi.nlm.nih.gov/pubmed/40193020

本文引用 [1]

[30]	华春珍, 俞蕙, 杨林海, 等. 儿童化脓性链球菌致中毒性休克综合征15例[J]. 中华儿科杂志, 2018, 56(8): 587-591. DOI: 10.3760/cma.j.issn.0578-1310.2018.08.006 . https://www.ncbi.nlm.nih.gov/pubmed/30078239 本文引用 [1]

[31]

Hasegawa

, Hashikawa

, Nakamura

, et al. Factors determining prognosis in streptococcal toxic shock-like syndrome: results of a nationwide investigation in Japan[J]. Microbes Infect, 2004, 6(12): 1073-1077. DOI: 10.1016/j.micinf.2004.06.001 .

https://www.ncbi.nlm.nih.gov/pubmed/15380776

本文引用 [1]

[32]	The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition[J]. JAMA, 1993, 269(3): 390-391. https://www.ncbi.nlm.nih.gov/pubmed/8418347 本文引用 [1]

[33]	Center for Disease Control and Prevention. Toxic shock syndrome (other than streptococcal) (TSS): 2011 case definition[EB/OL]. (2018-03-12)[2022-07-06]. https://ndc.services.cdc.gov/case-definitions/toxic-shock-syndrome-2011/ 本文引用 [1]

[34]

Nanduri

, Onukwube

, Apostol

, et al. Challenges in surveillance for streptococcal toxic shock syndrome: active bacterial core surveillance, United States, 2014-2017[J]. Public Health Rep, 2022, 137(4): 687-694. PMCID: PMC9257504. DOI: 10.1177/00333549211013460 .

https://www.ncbi.nlm.nih.gov/pubmed/33960856

本文引用 [1]

[35]	Song M, Huang X, Hou Y, et al. Perinatal group A streptococcal infection in vagina and its impact on pregnancy outcomes[J]. Am J Transl Res, 2024, 16(5): 1806-1814. PMCID: PMC11170569. DOI: 10.62347/ZKIE2772 . https://www.ncbi.nlm.nih.gov/pubmed/38883355 本文引用 [1]

[36]

Barsenga

, Mitiku

, Tesfa

, et al. Throat carriage rate, associated factors, and antimicrobial susceptibility pattern of group A Streptococcus among healthy school children in Jigjiga City, Eastern Ethiopia[J]. BMC Pediatr, 2022, 22(1): 227. PMCID: PMC9040231. DOI: 10.1186/s12887-022-03294-2 .

https://www.ncbi.nlm.nih.gov/pubmed/35473515

本文引用 [1]

[37]	Kim TH. Toxic shock syndrome (TSS) caused by group A Streptococcus: novel insights within the context of a familiar clinical syndrome[J]. J Korean Med Sci, 2024, 39(17): e154. PMCID: PMC11074494. DOI: 10.3346/jkms.2024.39.e154 . https://www.ncbi.nlm.nih.gov/pubmed/38711318 本文引用 [1]

[38]	Andreoni F, Zürcher C, Tarnutzer A, et al. Clindamycin affects group A Streptococcus virulence factors and improves clinical outcome[J]. J Infect Dis, 2017, 215(2): 269-277. DOI: 10.1093/infdis/jiw229 . https://www.ncbi.nlm.nih.gov/pubmed/27247345 本文引用 [1]

[39]	Gergova R, Boyanov V, Muhtarova A, et al. A review of the impact of streptococcal infections and antimicrobial resistance on human health[J]. Antibiotics (Basel), 2024, 13(4): 360. PMCID: PMC11047474. DOI: 10.3390/antibiotics13040360 . https://www.ncbi.nlm.nih.gov/pubmed/38667036 本文引用 [1]

[40]	Gregory CJ, Okaro JO, Reingold A, et al. Invasive group A streptococcal infections in 10 US states[J]. JAMA, 2025, 333(17): 1498-1507. PMCID: PMC11976646. DOI: 10.1001/jama.2025.0910 . https://www.ncbi.nlm.nih.gov/pubmed/40193120 本文引用 [1]

[41]

Iannelli

, Santoro

, Santagati

, et al. Type M resistance to macrolides is due to a two-gene efflux transport system of the ATP-binding cassette (ABC) superfamily[J]. Front Microbiol, 2018, 9: 1670. PMCID: PMC6079230. DOI: 10.3389/fmicb.2018.01670 .

https://www.ncbi.nlm.nih.gov/pubmed/30108557

本文引用 [1]

[42]	Yang Y, Xie S, He F, et al. Recent development and fighting strategies for lincosamide antibiotic resistance[J]. Clin Microbiol Rev, 2024, 37(2): e0016123. PMCID: PMC11237733. DOI: 10.1128/cmr.00161-23 . https://www.ncbi.nlm.nih.gov/pubmed/38634634 本文引用 [1]

[43]

Cortés-Penfield

, Ryder

. Should linezolid replace clindamycin as the adjunctive antimicrobial of choice in group A streptococcal necrotizing soft tissue infection and toxic shock syndrome? A focused debate[J]. Clin Infect Dis, 2023, 76(2): 346-350. DOI: 10.1093/cid/ciac720 .

https://www.ncbi.nlm.nih.gov/pubmed/36056891

本文引用 [1]

[44]

Babiker

, Warner

, Li

, et al. Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation[J]. Lancet Infect Dis, 2025, 25(3): 265-275. PMCID: PMC11871996. DOI: 10.1016/S1473-3099(24)00507-3 .

https://www.ncbi.nlm.nih.gov/pubmed/39396526

本文引用 [1]

[45]

Bryant

, Bayer

, Aldape

, et al. Emerging erythromycin and clindamycin resistance in group A Streptococci: efficacy of linezolid and tedizolid in experimental necrotizing infection[J]. J Glob Antimicrob Resist, 2020, 22: 601-607. DOI: 10.1016/j.jgar.2020.04.032 .

https://www.ncbi.nlm.nih.gov/pubmed/32408046

本文引用 [1]

[46]

Sriskandan

, Ferguson

, Elliot

, et al. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation[J]. J Antimicrob Chemother, 2006, 58(1): 117-124. DOI: 10.1093/jac/dkl173 .

https://www.ncbi.nlm.nih.gov/pubmed/16670109

本文引用 [1]

[47]	Amreen S, Brar SK, Perveen S, et al. Clinical efficacy of intravenous immunoglobulins in management of toxic shock syndrome: an updated literature review[J]. Cureus, 2021, 13(1): e12836. PMCID: PMC7896483. DOI: 10.7759/cureus.12836 . https://www.ncbi.nlm.nih.gov/pubmed/33628694 本文引用 [1]

[48]

Schrage

, Duan

, Yang

, et al. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome[J]. Clin Infect Dis, 2006, 43(6): 743-746. DOI: 10.1086/507037 .

https://www.ncbi.nlm.nih.gov/pubmed/16912949

本文引用 [1]

[49]

Laho

, Blumental

, Botteaux

, et al. Invasive group A streptococcal infections: benefit of clindamycin, intravenous immunoglobulins and secondary prophylaxis[J]. Front Pediatr, 2021, 9: 697938. PMCID: PMC8417895. DOI: 10.3389/fped.2021.697938 .

https://www.ncbi.nlm.nih.gov/pubmed/34490159

本文引用 [1]

[50]

Darenberg

, Ihendyane

, Sjölin

, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial[J]. Clin Infect Dis, 2003, 37(3): 333-340. DOI: 10.1086/376630 .

https://www.ncbi.nlm.nih.gov/pubmed/12884156

本文引用 [1]

[51]

Kaul

, McGeer

, Norrby-Teglund

, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. The Canadian Streptococcal Study Group[J]. Clin Infect Dis, 1999, 28(4): 800-807. DOI: 10.1086/515199 .

https://www.ncbi.nlm.nih.gov/pubmed/10825042

本文引用 [1]

[52]

Bergsten

, Madsen

, Bergey

, et al. Correlation between immunoglobulin dose administered and plasma neutralization of streptococcal superantigens in patients with necrotizing Soft tissue infections[J]. Clin Infect Dis, 2020, 71(7): 1772-1775. DOI: 10.1093/cid/ciaa022 .

https://www.ncbi.nlm.nih.gov/pubmed/31916575

本文引用 [1]

[53]	Cho KH. Molecular targets in Streptococcus pyogenes for the development of anti-virulence agents[J]. Genes (Basel), 2024, 15(9): 1166. PMCID: PMC11430994. DOI: 10.3390/genes15091166 . https://www.ncbi.nlm.nih.gov/pubmed/39336757 本文引用 [3]

[54]

Herrera

, Van Hove

, Hanson

, et al. Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection[J]. PLoS One, 2020, 15(6): e0235139. PMCID: PMC7310742. DOI: 10.1371/journal.pone.0235139 .

https://www.ncbi.nlm.nih.gov/pubmed/32574205

本文引用 [1]

[55]	Hansen NS, Leth S, Nielsen LT. Toxic shock syndrome[J]. Ugeskr Laeger, 2020, 182(20): V11190673. https://www.ncbi.nlm.nih.gov/pubmed/32400378 本文引用 [1]

[56]	禹定乐, 卢清华, 尤元海, 等. 中国儿童A族链球菌感染相关疾病的诊断、治疗与预防专家共识 [J]. 中华实用儿科临床杂志, 2022, 37(21): 1604-1618. DOI: 10.3760/cma.j.cn101070-20220815-00974 . 本文引用 [2]